MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Addi...
April 02 2018 - 04:30PM
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage
biopharmaceutical company focused on discovering and developing
innovative monoclonal antibody-based therapeutics for the treatment
of cancer, today announced the closing of its previously announced
underwritten public offering of shares of its common stock,
including the full exercise of the underwriters’ option to purchase
an additional 675,000 shares. The exercise of the underwriters’
option to purchase additional shares brought the total number of
shares of common stock sold by MacroGenics in the offering to
5,175,000 and increased the gross proceeds from the offering
(before deducting underwriting discounts and commissions and
estimated offering expenses) to approximately $110.0 million.
Leerink Partners, Deutsche Bank Securities and Evercore Group
L.L.C. acted as joint book-running managers of the offering.
Stifel, Nomura and SunTrust Robinson Humphrey acted as lead
managers and H.C. Wainwright & Co. acted as co-manager.
The shares were offered by MacroGenics pursuant to an effective
shelf registration statement that was previously filed with the
Securities and Exchange Commission (SEC). A final prospectus
supplement relating to and describing the terms of the offering was
filed with the SEC and is available on the SEC’s website at
www.sec.gov. Copies of the final prospectus supplement and the
accompanying prospectus relating to these securities may also be
obtained by contacting one of the following: Leerink Partners LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at 800-808-7525, ext. 6132 or by
email at syndicate@leerink.com; Deutsche Bank Securities Inc., 60
Wall Street, New York, New York 10005-2836, Attention: Prospectus
Group, Telephone: (800) 503-4611, E-mail: prospectus.cpdg@db.com;
or from Evercore Group L.L.C. at Attention: Equity Capital Markets,
55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone
at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
jurisdiction.
Cautionary Note on Forward-Looking
Statements
Any statements in this press release about prospective
financings, future expectations, plans and prospects for the
Company, including statements about the Company's strategy, future
operations, clinical development of the Company's therapeutic
candidates, milestone or opt-in payments from the Company's
collaborators, the Company's anticipated milestones and future
expectations and plans and prospects for the Company and other
statements containing the words "subject to", "believe",
"anticipate", "plan", "expect", "intend", "estimate", "project",
"may", "will", "should", "would", "could", "can", the negatives
thereof, variations thereon and similar expressions, or by
discussions of strategy constitute forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
uncertainties inherent in the initiation and enrollment of future
clinical trials, expectations of expanding ongoing clinical trials,
availability and timing of data from ongoing clinical trials,
expectations for regulatory approvals, market and other financing
conditions, other matters that could affect the availability or
commercial potential of the Company's product candidates and other
risks described in the Company's filings with the Securities and
Exchange Commission. In addition, the forward-looking statements
included in this press release represent the Company's views only
as of the date hereof. The Company anticipates that subsequent
events and developments will cause the Company's views to change.
However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so, except as may be
required by law. These forward-looking statements should not be
relied upon as representing the Company's views as of any date
subsequent to the date hereof.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company
focused on discovering and developing innovative monoclonal
antibody-based therapeutics for the treatment of cancer. The
Company generates its pipeline of product candidates primarily from
its proprietary suite of next-generation antibody-based technology
platforms, which have applicability across broad therapeutic
domains. MacroGenics, the MacroGenics logo and DART are trademarks
or registered trademarks of MacroGenics, Inc.
CONTACT:
Jim Karrels, Senior Vice President, CFO
MacroGenics, Inc.
1-301-251-5172, info@macrogenics.com
Karen Sharma, Vice President
MacDougall Biomedical Communications
1-781-235-3060, ksharma@macbiocom.com
MacroGenics (NASDAQ:MGNX)
Historical Stock Chart
From Feb 2024 to Mar 2024
MacroGenics (NASDAQ:MGNX)
Historical Stock Chart
From Mar 2023 to Mar 2024